Shire Extends Tender Offer for ViroPharma

barbara.lempert Shire Extends Tender Offer for ViroPharma DUBLIN, December 27, 2013 /PRNewswire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it has extended the expiration ...

Merck R&D adopts its rivals’ game plans in global overhaul

John Carroll When Merck announced back at the beginning of October that it was triggering a massive shakeup of its R&D operations after a 7-year blockbuster drought, the pharma ...

Aptalis files IPO after owner TPG Capital couldn’t find a buyer

Eric Palmer TPG Capital, unable to find a buyer willing to pay its $ 3 billion-plus asking price for Aptalis Pharma, is now going the IPO route, with a filing made Thursday ...

Report: Focus on Compliance Reduces Risk for Payers in the Medicare and Medicaid Markets

barbara.lempert Focus on Compliance Reduces Risk for Payers in the Medicare and Medicaid Markets, according to White Paper by TMG Health KING OF PRUSSIA, Pa., Dec. 27, 2013 /PRNewswire/ ...

Takeda suffers a big blow to its diabetes pipeline with PhIII failure of TAK-875

John Carroll Takeda has suffered a major setback in its quest to fill the blockbuster gap left by last year's loss of patent protection for the diabetes drug Actos. The pharma company ...

German Merck is among the companies fishing in Iran for more business

Eric Palmer With the prospect of sanctions easing, drugmakers are sizing up the opportunities in Iran, and Merck KGaA and others intend to seize them. FiercePharma News

China probes its largest hep B vaccine maker after child deaths

Eric Palmer China, which has been trying to demonstrate adequate oversight of its growing drug industry, is investigating two of its key vaccinemakers after the deaths of 8 children ...

Reports Indicate Co-Managed Care Popular Among Older Adults with Low Back Pain

barbara.lempert CARMICHAEL, Calif., Dec. 26, 2013–(BUSINESS WIRE)–The Foundation for Chiropractic Progress (F4CP), a not-for-profit organization dedicated to raising awareness ...

Ikaria takes a $1.6B buyout but spins out some early-stage programs

Damian Garde Rumored takeover target Ikaria has signed a deal to sell the majority of its business to a private equity outfit for about $ 1.6 billion, spinning out a new company to ...

Novo gets a year-end win for Factor XIII blood-clotting product after two rejections

Eric Palmer Three's a charm for Novo Nordisk and its recombinant Factor XIII compound for a rare bleeding disorder. After receiving a complete response letter in 2012 and then again ...

Compounder Strikes Preliminary $100M Deal Over Meningitis Outbreak

esilverman More than a year after an outbreak of fungal meningitis was traced to the New England Compounding Center and caused the worst public health crisis in the US in decades, ...

Genocea pitches $75M IPO to back T-cell vaccine pipeline work

John Carroll Genocea Biosciences is throwing its hat in the growing IPO ring. The biotech has laid out plans to raise $ 75 million to help fund its work on a pair of early-stage T-cell ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS